Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D0YM
|
|||
| Former ID |
DIB002566
|
|||
| Drug Name |
Amosulalol
|
|||
| Synonyms |
Lowgan; LY-137224; YM-09538
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Company |
Yamanouchi Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H24N2O5S
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
|
|||
| InChI |
1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
|
|||
| InChIKey |
LVEXHFZHOIWIIP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 85320-68-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:135592
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [1], [2] |
| Adrenergic receptor beta-3 (ADRB3) | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Salivary secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta3 adrenergic receptor signaling pathway | ||||
| Alpha adrenergic receptor signaling pathway | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.